Close

Jefferies Cuts Target on Rigel Pharmaceuticals (RIGL) on Fostamatinib Setback

June 5, 2013 8:00 AM EDT Send to a Friend
Jefferies cut its price target on Rigel Pharmaceuticals (NASDAQ: RIGL) from $7 to $6 after AstraZeneca returned rights to fostamatinib ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login